Yarrow Bioscience (YARW) Non-Current Assets (2016 - 2026)
Yarrow Bioscience's (YARW) quarterly Non-Current Assets came in at $84000.0 in Q1 2026, down 94.44% YoY from $1.5 million in Q1 2025, and down 44.0% on a QoQ basis from $150000.0 in Q4 2025.
Yarrow Bioscience (YARW) Non-Current Assets (2016 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 11 years of Non-Current Assets data on file, last reported at $84000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 94.44% year-over-year to $84000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84000.0 (down 94.44% YoY) and the FY2025 annual result came in at $150000.0, down 93.92% from the prior year.
- Non-Current Assets declined to $84000.0 in Q1 2026, from $150000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $3.7 million in Q1 2022 to a low of $84000.0 in Q1 2026.
- A 5-year average of $2.0 million and a median of $2.1 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets jumped 51.65% — and 2026, when it slumped 94.44%.
- Tracing YARW's Non-Current Assets over 5 years: stood at $2.5 million in 2022, then plunged by 30.65% to $1.7 million in 2023, then jumped by 43.32% to $2.5 million in 2024, then tumbled by 93.92% to $150000.0 in 2025, then slumped by 44.0% to $84000.0 in 2026.
- The last three Non-Current Assets figures came in at $84000.0 (Q1 2026), $150000.0 (Q4 2025), and $375000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 84,000.00 |
| Dec 31, 2025 | 150,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.66 Mn |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.48 Mn |
| Sep 30, 2022 | 2.86 Mn |
| Jun 30, 2022 | 3.27 Mn |
| Mar 31, 2022 | 3.67 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.56 Mn |